Sanofi Invests $18.96 Million in Immuneering Corporation $IMRX

Sanofi bought a new stake in shares of Immuneering Corporation (NASDAQ:IMRX) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 2,708,559 shares of the company’s stock, valued at approximately $18,960,000. Immuneering makes up approximately 7.3% of Sanofi’s portfolio, making the stock its 5th largest position. Sanofi owned 6.52% of Immuneering at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Jane Street Group LLC purchased a new position in shares of Immuneering during the first quarter valued at about $32,000. Future Financial Wealth Managment LLC purchased a new position in Immuneering during the 3rd quarter valued at approximately $35,000. Kingsview Wealth Management LLC bought a new stake in Immuneering in the 2nd quarter worth approximately $47,000. XTX Topco Ltd purchased a new stake in shares of Immuneering during the 2nd quarter worth approximately $90,000. Finally, Wendell David Associates Inc. purchased a new stake in Immuneering during the third quarter valued at $105,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on IMRX shares. Chardan Capital restated a “buy” rating and set a $20.00 target price on shares of Immuneering in a research report on Thursday, November 13th. Leerink Partners initiated coverage on Immuneering in a research note on Friday, October 31st. They set an “outperform” rating and a $15.00 price objective on the stock. Wall Street Zen lowered shares of Immuneering from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Mizuho set a $12.00 price target on shares of Immuneering in a report on Wednesday, October 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Insider Transactions at Immuneering

In other news, Director Peter Feinberg acquired 20,000 shares of Immuneering stock in a transaction dated Monday, January 12th. The stock was purchased at an average cost of $4.35 per share, for a total transaction of $87,000.00. Following the completion of the purchase, the director directly owned 135,441 shares in the company, valued at $589,168.35. This trade represents a 17.32% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Thomas J. Schall bought 21,645 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The shares were purchased at an average cost of $4.67 per share, with a total value of $101,082.15. Following the acquisition, the director directly owned 74,530 shares of the company’s stock, valued at approximately $348,055.10. This trade represents a 40.93% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 51,819 shares of company stock worth $234,472 over the last three months. Corporate insiders own 22.90% of the company’s stock.

Immuneering Stock Down 4.9%

Shares of Immuneering stock opened at $4.63 on Friday. The company has a 50 day moving average price of $5.99 and a 200 day moving average price of $5.87. The firm has a market capitalization of $298.96 million, a P/E ratio of -2.60 and a beta of 0.48. Immuneering Corporation has a 52 week low of $1.10 and a 52 week high of $10.08.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). As a group, research analysts anticipate that Immuneering Corporation will post -1.86 earnings per share for the current fiscal year.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.